Key result
In patients with heart failure and reduced ejection fraction, ivabradine reduces cardiovascular mortality by 17%, heart failure mortality by 39%, and heart failure hospitalization by 30%.
Why the study?
Does ivabradine reduce cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate?
Does ivabradine reduce cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate?
Ivabradine is an effective treatment for reducing cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF patients with elevated resting heart rate despite beta-blocker therapy.
No takes yet. Share an insight, caveat, or question.
May support ivabradine consideration in HFrEF; leaves open definitive efficacy confirmation in RCTs.
Müller‐Werdan et al. (2016) conducted a review in Heart failure with reduced ejection fraction. Ivabradine was evaluated. In patients with heart failure and reduced ejection fraction, ivabradine reduces cardiovascular mortality by 17%, heart failure mortality by 39%, and heart failure hospitalization by 30%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: